Marek\u27s Disease Virus (MDV) Encodes an Interleukin-8 Homolog (vIL-8): Characterization of the vIL-8 Protein and a vIL-8 Deletion Mutant MDV by Parcells, Mark S et al.
Dartmouth College 
Dartmouth Digital Commons 
Open Dartmouth: Published works by 
Dartmouth faculty Faculty Work 
6-2001 
Marek's Disease Virus (MDV) Encodes an Interleukin-8 Homolog 
(vIL-8): Characterization of the vIL-8 Protein and a vIL-8 Deletion 
Mutant MDV 
Mark S. Parcells 
University of Arkansas 
Su-Fang Lin 
Case Western Reserve University 
Robert L. Dienglewicz 
University of Arkansas 
Vladimir Majerciak 
Slovak Academy of Sciences 
Dan R. Robinson 
Case Western Reserve University 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.dartmouth.edu/facoa 
 Part of the Animal Sciences Commons, Medical Microbiology Commons, and the Virus Diseases 
Commons 
Dartmouth Digital Commons Citation 
Parcells, Mark S.; Lin, Su-Fang; Dienglewicz, Robert L.; Majerciak, Vladimir; Robinson, Dan R.; Chen, Hua-
Chien; Wu, Zining; Dubyak, George R.; Brunovskis, Peter; and Hunt, Henry D., "Marek's Disease Virus (MDV) 
Encodes an Interleukin-8 Homolog (vIL-8): Characterization of the vIL-8 Protein and a vIL-8 Deletion 
Mutant MDV" (2001). Open Dartmouth: Published works by Dartmouth faculty. 1118. 
https://digitalcommons.dartmouth.edu/facoa/1118 
This Article is brought to you for free and open access by the Faculty Work at Dartmouth Digital Commons. It has 
been accepted for inclusion in Open Dartmouth: Published works by Dartmouth faculty by an authorized 
administrator of Dartmouth Digital Commons. For more information, please contact 
dartmouthdigitalcommons@groups.dartmouth.edu. 
Authors 
Mark S. Parcells, Su-Fang Lin, Robert L. Dienglewicz, Vladimir Majerciak, Dan R. Robinson, Hua-Chien 
Chen, Zining Wu, George R. Dubyak, Peter Brunovskis, and Henry D. Hunt 
This article is available at Dartmouth Digital Commons: https://digitalcommons.dartmouth.edu/facoa/1118 
JOURNAL OF VIROLOGY,
0022-538X/01/$04.0010 DOI: 10.1128/JVI.75.11.5159-5173.2001
June 2001, p. 5159-5173 Vol. 75, No. 11
Copyright © 2001, American Society for Microbiology. All Rights Reserved.
Marek’s Disease Virus (MDV) Encodes an Interleukin-8 Homolog (vIL-8):
Characterization of the vIL-8 Protein and a vIL-8
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Chemokines induce chemotaxis, cell migration, and inflammatory responses. We report the identification of
an interleukin-8 (IL-8) homolog, termed vIL-8, encoded within the genome of Marek’s disease virus (MDV).
The 134-amino-acid vIL-8 shares closest homology to mammalian and avian IL-8, molecules representing the
prototype CXC chemokine. The gene for vIL-8 consists of three exons which map to the BamHI-L fragment
within the repeats flanking the unique long region of the MDV genome. A 0.7-kb transcript encoding vIL-8 was
detected in an n-butyrate-treated, MDV-transformed T-lymphoblastoid cell line, MSB-1. This induction is es-
sentially abolished by cycloheximide and herpesvirus DNA polymerase inhibitor phosphonoacetate, indicating
that vIL-8 is expressed with true late (g2) kinetics. Baculovirus-expressed vIL-8 was found to be secreted into
the medium and shown to be functional as a chemoattractant for chicken peripheral blood mononuclear cells
but not for heterophils. To characterize the function of vIL-8 with respect to MDV infection in vivo, a recom-
binant MDV was constructed with a deletion of all three exons and a soluble-modified green fluorescent protein
(smGFP) expression cassette inserted at the site of deletion. In two in vivo experiments, the vIL-8 deletion mu-
tant (RB1BvIL-8DsmGFP) showed a decreased level of lytic infection in comparison to its parent virus, an
equal-passage-level parent virus, and to another recombinant MDV containing the insertion of a GFP expres-
sion cassette at the nonessential US2 gene. RB1BvIL-8DsmGFP retained oncogenicity, albeit at a greatly re-
duced level. Nonetheless, we have been able to establish a lymphoblastoid cell line from an RB1BvIL-8DsmGFP-
induced ovarian lymphoma (MDCC-UA20) and verify the presence of a latent MDV genome lacking vIL-8.
Taken together, these data describe the identification and characterization of a chemokine homolog encoded with-
in the MDV genome that is dispensable for transformation but may affect the level of MDV in vivo lytic infection.
Marek’s disease (MD) is a contagious, lymphoproliferative
disease of domestic chickens in which mononuclear infiltra-
tion, demyelination of peripheral nerves, and T-cell lympho-
mas are common features (52). The etiologic agent of MD is a
lymphotropic herpesvirus, MD virus (MDV), which can elicit
rapid-onset T-cell lymphomas in chickens within several weeks
of infection (reviewed in references 12 and 56). The severity of
the symptoms usually correlates with the extent of viral repli-
cation in target cells. While the exact route of infection is not
completely understood, cytolytic infection of B cells, followed
by the latent infection of T cells, is thought to be among the
crucial steps. During this initial process, a productive infection
requires the successful recruitment of the host target cells,
without eliciting strong host immune responses. The virus en-
ters a latent state in T cells within 1 to 2 weeks postinfection
and thereafter induces malignant transformation in this cell
type. Vaccines that target this initial stage and diminish the
virulence of incoming MDV have been developed. Despite
this success, sporadic outbreaks of MD, due to newly evolved
strains of MDV with increased virulence, have been reported
(67). Knowledge of the pathways by which MDV infects and
responds to cells of the host immune system is crucial to our
understanding of the tumor biology of MD and the develop-
ment of improved control strategies.
A number of gammaherpesviruses express genes related to
cellular chemokines (47). Chemokines are collectively known
as a family of structurally related cytokines that induce che-
motaxis, or directed migration, of leukocyte subsets to the sites
invaded by microbes (1). Thus, chemokines play important
roles in cellular inflammation, both in the protective responses
to the intruding pathogens and in the pathological processes
associated with infection (55). Chemokines have been catego-
rized into four subfamilies according to their protein structure,
namely, CXC (or a), CC (or b), CXXXC (CX3C) fractalkine,
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and lymphotactin (1). The basis for this structural classification
is the spacing of four invariable cysteines in all CXC and CC
chemokines. The first two cysteines of CXC (CXXXC) che-
mokines are separated by 1 (3) intervening amino acid resi-
due(s), while those in the CC subfamily are adjacent. Lympho-
tactin, on the other hand, is distinguished by possessing only 2,
rather than 4, cysteines (29).
Structural analysis of interleukin 8 (IL-8), the prototype
CXC chemokine, helped to define the critical residues that
interact with the receptor to activate signaling pathways in the
leukocytes that they recruit (15). IL-8 was originally identified
as a monocyte-derived factor that attracts neutrophils in Boy-
den chamber assays (60, 66, 70). IL-8 recruits neutrophils in
vivo by promoting cell adhesion and transendothelial migra-
tion abilities (2, 62). The recruited target cells become ac-
tivated and exhibit biochemical properties, such as degran-
ulation, oxidative burst, and calcium influx, leading to the
enhancement of killing (5, 6). Viral infections are often accom-
panied by the upregulation of cellular IL-8 or other related
chemokines (26, 41–43, 64).
The IL-8 homolog of chickens, 9E3/CEF4, was originally
identified as an upregulated gene in Rous sarcoma virus-trans-
formed cells (9, 64). This chemokine and a homologous che-
mokine, K60, were recently cloned from an activated chicken
macrophage cell line cDNA library (28, 61) and show homol-
ogy to IL-8 and growth-regulated protein alpha (Gro-a) (28,
38, 61). 9E3/CEF4, like IL-8, is greatly upregulated at sites of
wounding (37) and appears to mitigate the healing cascade
(36). Overproduction of IL-8 can be part of the host defense
system but has been implicated also in inflammatory disorders,
such as psoriasis (11) and rheumatoid arthritis (48). In some
instances, IL-8-like chemokines, such as 9E3/CEF4, display
strong angiogenic properties with a consequence of stimulating
tumor cell growth (37) as well as stimulating growth of chick
embyro fibroblasts (CEF) in culture (7).
We report here the identification and characterization of
a CXC chemokine encoded within the repeated sequences
flanking the unique long (UL) region of the MDV genome.
This chemokine has been termed vIL-8 because of its high
level of homology to cellular IL-8 families, including chicken
9E3/CEF4 and K60 (61). We have found that the MDV gene
encoding vIL-8 is expressed with true late kinetics, its ex-
pression being abolished in both cycloheximide (CHX) and
phosphonoacetic acid (PAA)-treated cells. Using a baculo-
virus expression system, we have found that vIL-8 is secreted
and functions as a chemoattractant for chicken mononuclear
cells but not for heterophils. In addition, to explore the
function of vIL-8 during the course of MDV infection, both
copies of the vIL-8 genes in the RB1B genome were re-
placed with a soluble-modified green fluorescent protein
(smGFP) expression cassette, yielding a vIL-8 null mutant,
termed RB1BvIL-8DsmGFP. In this paper, we describe the
growth kinetics of RB1BvIL-8DsmGFP in cell culture, the
oncogenicity of RB1BvIL-8DsmGFP in chickens, and the
establishment of a T-lymphoblastoid cell line derived from
tumors induced by RB1BvIL-8DsmGFP infection.
MATERIALS AND METHODS
Cells and viruses. MSB-1 cells (3) were grown at 37°C in RPMI 1640 supple-
mented with 10% fetal bovine serum in the presence of 5% CO2. Virus replica-
tion was induced by the treatment of log-phase cells with 3 mM n-butyrate for
48 h or various time periods as noted. For MDV propagation, secondary CEF
were prepared essentially as described (40) using specific-pathogen-free (SPF),
10-day-old embryonated eggs (Sunrise Inc., Catskill, N.Y.). MDV strain RB1B,
a very virulent pathotype virus (58), was used for recombinant construction and
was obtained from Robin W. Morgan, University of Delaware.
RACE. The assays for rapid amplification of cDNA ends (RACE) were es-
sentially identical to the procedures reported by Frohman et al. (19) with the
following modifications. Specifically, polyadenylated [poly(A)] RNA was purified
using oligo(dT) cellulose (type 7; Pharmacia, Piscataway, N.J.) spin columns. For
first-strand synthesis, 2.5 mg of poly(A) RNA was primed with SS-dT oligonu-
cleotides (Table 1), for 39 RACE or dT20 for 59 RACE, and reverse transcription
(RT) was carried out using avian myeloblastosis virus-reverse transcriptase
(Boehringer Mannheim, Indianapolis, Ind.) at 42°C for 1 h using the conditions
specified by the manufacturer. The resulting first-strand cDNA was used directly
as the DNA template in 39 RACE. The DNA template for 59 RACE was
prepared by further treatment of the first strand cDNA with 60 U of terminal
deoxynucleotidyltransferase (GIBCO-BRL, Gaithersburg, Md.) in the presence
of 0.2 mM dATP for 15 min at 37°C. The second-strand synthesis was then
primed with SS-dT primer and incubated with 120 U of T4 DNA polymerase;
24 U of Escherichia coli DNA ligase; and 5 U of RNase H in a buffer containing
0.2 mM dNTP, 100 mM KCl, 10 mM ammonium sulfate, 5 mM MgCl2, 0.15 mM
b NAD, 20 mM Tris-HCl (pH 7.5), and 50 mg of bovine serum albumin/ml for 4 h
at 15°C. Primers used in 59 RACE were single stranded (SS) (Table 1). Primers
used in 39 RACE were SS and vIL-8F4 (Table 1). PCR conditions for denatur-
ation, annealing, and polymerization were 93°C for 50 s, 56°C for 1 min, and 68°C
for 3 min for 59 RACE; and 93°C for 45 s, 60°C for 1 min, and 68°C for 4 min for
39 RACE. High-fidelity Taq polymerase (Boehringer Mannheim) was used in all
the RACE assays, and 30 cycles of amplification was applied to each reaction.
PCR products were subsequently cloned into the pCR2.1-TOPO vector (Invitro-
gen, Carlsbad, Calif.).
DNA sequence analysis. The DNA sequence of each RACE insert was deter-
mined on both strands by a dideoxynucleotide chain termination method. The
DNA sequences of RACE clones were compiled, aligned, and analyzed using
MacVector (6.0) software. Deduced amino acid secondary structures were ana-
lyzed by Chou-Fasman, Kyte-Doolittle, or Robson-Garnier programs. Alignment
of vIL-8 sequence with its mammalian homologs was performed by ClustalW
profiling.
Kinetics of vIL-8 expression analysis. (i) Northern blot analysis. Cells were
lysed in TRIZOL solution (GIBCO-BRL), and total cellular RNA was isolated
as specified by the manufacturer. Twenty micrograms of total RNA from each
sample was separated by electrophoresis through a formaldehyde–1.2% agarose
gel and blotted overnight to a nylon membrane (Nytran; Schleicher & Schuell) by
standard procedures (4). The DNA probe used to detect the vIL-8 transcript was
PCR amplified from the genomic DNA of MSB-1 cells, using primers vIL8B1
and vIL8F4. DNA probes for meq and chicken glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) were from respective subclones as described previously
(63).
(ii) RT-PCR analysis. To firmly establish the kinetics of vIL-8 expression,
DNA-free RNA was purified from 60-mm-diameter dishes of CEF infected with
10,000 PFU of RB1B-infected CEF in the presence or absence of 100 mg of CHX
(Sigma)/ml or 100 mg of PAA (Sigma)/ml. CEF were plated for 2 h prior to the
addition of CHX and PAA, and the inocula were thawed from frozen stocks,
divided into equal aliquots, pelleted by centrifugation, and resuspended in
growth medium containing the chemicals at the given concentrations. The in-
fected cells were plated, and the infections were allowed to proceed for 24 h
(37°C, 5% CO2). RNA was purified using RNAeasy (Qiagen Corp., Chatsworth,
Calif.) and quantitated spectrophotometrically. To evaluate the kinetic class of
MDV gene expression, primers were designed to amplify MDV genes of known
kinetic class: immediate-early (IE), ICP27 (Table 1); early (E), the large subunit
of ribonucleotide reductase (RRL) (Table 1); true late (L), gC (Table 1) as well
as vIL-8 and Meq (Table 1). RT-PCR was performed using 500, 50, and 5 ng of
RNA as template and the MasterAmp RT-PCR kit (Epicentre Technologies,
Madison, Wis.). For RT-PCR, the following amplification conditions were used:
40 min at 60°C (RT step), 5 min at 95°C (initial denaturation), and 40 cycles of
95°C for 1 min, 55°C for 1 min, and 72°C for 2 min. The amplification terminated
with a final elongation step of 7 min at 72°C. Amplified products were separated
on a 1% agarose gel (13 Tris-borate-EDTA [TBE]), and images were acquired
using the Gel-Doc system (Bio-Rad, Hercules, Calif.).
Plasmids. An 18-bp sequence which encodes six histidines was fused to the
39 end of the coding region of vIL-8 by PCR amplification using primers 5vIL-
8NHE and vIL-8HIS (Table 1). The resulting PCR product was cloned into a
baculovirus expression vector, pBlueBac2 (Invitrogen), as an 845-bp NheI-
5160 PARCELLS ET AL. J. VIROL.
BamHI restriction fragment. The baculovirus-based expression construct, pBB2-
vIL-8H, was confirmed by DNA sequence analysis.
For recombinant MDV construction, the BamHI-L fragment of the MDV
genome (20) was used. The region encoding all three exons of vIL-8 was deleted
from the BamHI-L fragment via excision of an 804-bp NcoI-ClaI fragment. An
smGFP (17) expression cassette was constructed using dual expression vector
pBKCMV (Stratagene, La Jolla, Calif.). Briefly, plasmid pBKCMV-smGFP has
the open reading frame for smGFP fused in frame to the LacZ-alpha peptide in
pBKCMV to yield a vector that expresses smGFP in E. coli (via the lac promoter)
as well as in eucaryotic cells (via cytomegalovirus [CMV], i.e., promoter). This
plasmid also contained a deletion of the simian virus 40 59 splice donor/splice
acceptor region downstream of smGFP. This region was removed as a 357-bp
NotI-BclI fragment. The resulting smGFP expression cassette was contained
within a 1,813-bp AseI-MluI fragment. This fragment was excised, blunt ended
with the Klenow enzyme, and inserted into the blunt-ended NcoI-ClaI sites of the
BamHI-L fragment with deletion of vIL-8. Recombinant plasmids were screened
for smGFP expression and cassette orientation. Plasmid pYH6a has the smGFP
expression cassette inserted in the same orientation as the original vIL-8 gene
(see Fig. 7A).
Preparation of vIL-8–His fusion protein. The baculovirus expression system
was used to express recombinant vIL-8 protein. DNA encoding vIL-8 with six
contiguous histidines tagged to its C terminus was inserted into baculovirus
expression vector pBlueBac2. Insect Spodoptera frugiperda (Sf9) cells cotrans-
fected with the expression vector and Bac-N-Blue linear AcMNPV DNA (In-
vitrogen) were used for generating high-titer recombinant baculovirus as de-
scribed previously (69). High Five (Invitrogen) insect cells grown as suspension
cultures in serum-free Express Five (GIBCO-BRL) medium were chosen for the
production of recombinant vIL-8 protein. Briefly, cell-free supernatant was col-
lected 72 h postinfection from cells infected with high-titer vIL-8–His recombi-
nant viruses by centrifugation, concentrated 10-fold, and dialyzed into column
buffer (50 mM Na phosphate, pH 8.0, containing 0.5 M NaCl and 20 mM
imidazole) before being loaded onto a metal affinity column (Ni-resin; Novagen).
After washing with 10 column volumes, proteins bound to the Ni-resin were
eluted with a linear gradient of imidazole (20 to 500 mM) in column buffer.
Fractions containing vIL-8–His (as judged by sodium dodecyl sulfate [SDS]–10 to
20% polyacrylamide gel electrophoresis [PAGE]) were pooled and dialyzed
against phosphate-buffered saline. The resulting sample was concentrated eight-
fold using Centricon-3 filter units (Millipore) and subjected to gel filtration
chromatography (Superose 12 column; Pharmacia). Fractions were collected
every 2 min at a flow rate of 0.4 min/ml and were analyzed by SDS–10 to 20%
PAGE followed by silver staining.
Chemotaxis assay. For cell separation, 25 ml of fresh chicken whole blood was
layered over an equal volume of 1-Step Polymorphs solution (Accurate Chemical
and Scientific Co., Westbury, N.Y.) and centrifuged 30 min at 475 3 g (20°C).
Peripheral blood mononuclear cells (PBMC) and heterophils were separated
into two distinct bands free from red blood cells after centrifugation and were
collected and washed as specified by the manufacturer’s instructions. Cells were
resuspended in RPMI 1640 medium at a concentration of 106/ml. For the che-
motaxis assay, a 12-well Costar Transwell (Corning Costar Co., Cambridge,
Mass.) apparatus was used. Serial dilutions of purified vIL-8–His or recombinant
human IL-8 (hIL-8) (R & D Systems, Minneapolis, Minn.) were made in RPMI
1640 medium, and 600 ml of each dilution was applied to the lower chamber of
the assay wells and covered with a polycarbonate membrane with a 3-mm pore
size for heterophils and 5-mm pore size for PBMC. A 100-ml cell suspension was
then added to the top wells. The assay plates were incubated at 37o for 60 min
for heterophils and for 40 min for PBMC. The cells in the lower chamber were
then counted with a microscope (Nikon-TMS, Tokyo, Japan). Fibronectin (25
mg/ml [57 nM], Boehringer Mannheim) and medium alone were included in each
experiment to serve as positive and negative controls, respectively.
Recombinant MDV construction. RB1BvIL-8DsmGFP was constructed using
RB1B-infected CEF DNA and the pYH6a transfer vector as described for
lacZ-containing mutant MDVs (45) with minor modification. Essentially, 10 mg
of RB1B-infected CEF DNA (RB1Bp12) was transfected with various concen-
trations of pYH6a (10, 50, 100, and 500 ng) via the calcium phosphate method
optimized for MDV (40). At 6 days postinfection, fluorescent plaques were
identified and passaged onto fresh CEF via scraping with a micropipette into 0.5
ml of 0.5% trypsin/EDTA (Sigma). After dissociation of the cells comprising the
plaque (2 to 3 min), the trypsin was inactivated via the addition of 50 ml of
TABLE 1. Primers used in vIL-8 analysis
Gene Primer sequences Product (bp) Reference
Chicken b-actin ACTF4: 59-CCATGAAACTACCTTCAACTCCA-39 628 (unspliced)
ACTR4: 59-GATTCATCGTACTCCTGCTTGCT-39 274 (spliced) 30
gC gCF: 59-TACTCTGCGATACGGAAG-39 584 31
gCR: 59-GAGGAGTTGCAATGTTTCC-39
GFP GFPF: 59-CTTGTTGAATTAGATGGTGATGTT-39 584 17
GFPR: 59-TTTCGAAAGGG-CAGATTGTG-39
ICP27 ICP27F: 59-GCAAGAAGGGCATCACCGAAGAA-39 670 56
ICP27R: 59-ACGACGAATGCGCGATAACAAAAT-39
Meq MEQF: 59-CCCCTTCCCTGACGGCCTATCTGA-39 421 27
MEQR: 59-CTGGGCGCAAAGTTCCTCCGTATC-39
RRL RRLF: 59-GCCGCCGTTGCTATTTCTCTA-39 549 31
RRLR: 59-ATGACGCGTGATGCCAACAAC-39
vIL-8 (His tagged) 5vIL-8NHE: 59-GCACGCTAGCCGCCACCATGCAGGCGTTGTTGCTAG-39 845 This report
vIL-8HIS: 59-CGGGATCCTAGTGATGATGATGGTGATGAAGACAGATATGGGA-39
vIL-8 (structural analysis) vIL-8 no. 1: 59-GGAGACCCAATAAC-AGGGAAATCGC-39 939 This report
vIL-8 no. 4: 59-CGACAGACAGTTGTACACCTGCCTG-39
vIL-8 (RT-PCR) vIL8F: 59-TGCAGGCGTTGTTG-CTAGTATTGGTT-39 699 (unspliced) This report
vIL8R: 59-ACAGGAGGTAGCAATTAATCAAAGAGA-39 423 (spliced)
vIL-8 (SS) 59-CGTAGGTTACCGTATCGGATAG-39 See Fig. 2 This report
vIL-8 (vIL-8B1) 59-GGTCCACACATACCTTCCTGTTCTTC-39 See Fig. 2 This report
vIL-8 (SS-dT) 59-CGTAGGTTACCGTATCGGATAGCGGCCGCATTTTTTTTTTTTTTTTTT-39 See Fig. 2 This report
vIL-8 (vIL-8F4) 59-GCAAGTGCGTGAAAGTCACTAATCG-39 See Fig. 2 This report
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filter-sterilized calf serum (GIBCO-BRL). The cells were then added to freshly
plated secondary CEF on 60-mm-diameter gridded dishes (2 3 106 cells/dish) or
diluted to 10 ml with complete medium (M199; 3% [vol/vol] calf serum; and
penicillin, streptomycin, and neomycin [GIBCO-BRL]) and were spread across
96-well plates (100 ml of plaque suspension per well) that were plated with
uninfected secondary CEF (1.25 3 104/well). Wells containing single, fluorescent
plaques were then harvested via trypsin treatment and passaged again in 60-mm-
diameter dishes and/or 96-well plates (as described above). This process was
repeated until all formed plaques were fluorescent. At this point, stocks of
mutant virus were made. The results presented here were obtained using one of
four clones of RB1BvIL-8DsmGFP.
Structural analysis of RB1B and RB1BvIL-8DsmGFP genomes. To confirm
the deletion of the vIL-8-encoding region from the MDV genome, PCR primers
were designed that hybridize to sequences flanking the site of deletion. These
primers are vIL-8 no. 1 and vIL-8 no. 4 (Table 1), which correspond to nucleo-
tides (nt) 848 to 872 and the reverse complement of nt 1762 to 1786 of the
BamHI-L fragment of the MDV genome, inclusive (31). The resulting PCR
product is therefore 939 bp using the parental (RB1B) virus as template and 1948
bp using the mutant (RB1BvIL-8DsmGFP) virus as template, due to vIL-8
deletion and expression cassette insertion. To further confirm the structure of
RB1BvIL-8DsmGFP, these PCR products were subjected to Southern blot hy-
bridization analysis using the BamHI-L fragment, the deleted fragment (NcoI-
ClaI), and GFP-specific probes. PCR-amplified products were separated via
electrophoresis using a 1% agarose–13 TBE gel, transferred to nylon mem-
branes (Nytran; Schleicher & Schuell) via capillary transfer (57), and subjected
to UV cross-linking for immobilization (Stratalinker; Stratagene). The probes
were labeled directly via cross-linking with alkaline phosphatase (Alk-Phos Di-
rect; Amersham-Pharmacia). Prehybridization of blots, probe hybridization, and
subsequent washes were performed according to the instructions of the manu-
facturer. After washing and substrate addition, blots were subject to autolumi-
nography using X-ray film (X-OMAT-MR; Kodak, Rochester, N.Y.).
Expression analysis of RB1BvIL-8DsmGFP. To correlate the deletion of the
vIL-8 gene with a functional loss in gene expression, we performed RT-PCR
analysis using total RNA purified from RB1B-, RB1BvIL-8DsmGFP-, and un-
infected CEF (RNAeasy, Qiagen). The primers used were specific for (i) the
chicken b-actin gene (exon IV3exon V, 628 bp [unspliced], 274 bp [spliced]),
ACTF4 and ACTR4 (30); (ii) the smGFP gene (584-bp product), GFPF and
GFPR (17); (iii) the MDV ICP27 gene (670-bp product), ICP27F and ICP27R
(54); and (iv) the vIL-8 gene (exon I3exon III, 699 bp [unspliced], 423 bp
[spliced]), vIL-8F and vIL-8R (Table 1). RT-PCR was performed using a Mas-
terAmp RT-PCR kit (Epicentre Technologies) and serial dilutions of total RNAs
(1 mg, 100 ng, or 10 ng per reaction). All primers were used at a concentration
of 0.25 pmol per reaction. The program for the amplifications consisted of one
cycle of 60°C for 40 min followed by one cycle of 95°C for 3 min and 30 cycles of
95°C for 1 min, 50°C for 1 min, and 72°C for 2 min. The reactions then had one
final elongation step (72°C) for 7 min and were then held at 4°C until analyzed.
For each gel, 10 ml of reaction products was separated on a 1% agarose gel in 13
TBE containing 0.5 mg of ethidium bromide per ml, as described previously
(57). As a control for DNA contamination of RNA samples, chicken b-actin
and vIL-8 primers were designed to span at least one intron. In addition, 20
ng of RB1B-infected CEF DNA was used as a control for vIL-8 gene ampli-
fication.
Characterization of RB1BvIL-8DsmGFP infection in vivo. In order to char-
acterize the function of the vIL-8 gene during infection, two independent in vivo
studies were conducted. These studies were performed in the John Kirkpatrick
Skeeles Poultry Health Laboratory, a biosecurity facility at the University of
Arkansas. All work was performed at biosafety level 3 using animal rooms under
negative pressure with high-efficiency particulate-filtered air entering and leaving
each room. The birds were housed in glove box isolators and given a commercial
starter feed and water ad libitum.
In vivo study 1. This study employed SPF chickens (B15 3 7) provided as
embryonated eggs by Richard L. Witter (USDA-ARS, Avian Disease and On-
cology Laboratory, East Lansing, Mich.). For each virus-infected group, 25
1-day-old birds were injected with approximately 1,000 PFU of virus-infected
CEF in 0.2 ml of medium via the intra-abdominal route. As mock-infected
controls, 25 birds were injected with uninfected CEF. The titer was determined
for each virus used via cocultivation of 10 and 100 ml of inoculum with secondary
CEF. At 7, 14, 21, and 28 days postinoculation, three birds were removed from
each treatment group for virus reisolation from peripheral blood leukocytes
(PBL) and spleen cells. Cells were collected as previously described (45) and
were cocultivated with freshly plated secondary CEF. Remaining chickens were
maintained in isolation and monitored daily for the development of signs of MD
(paralysis, depression, torticollis, etc.), and birds exhibiting severe signs were
culled for necropsy and cell line establishment At 9 weeks postinoculation, all
remaining birds were euthanatized and necropsied, and the number and site of
MD-associated lesions were recorded.
In vivo study 2. This study was performed essentially as described above, with
the exception that commercially obtained SPF White Leghorn chickens were
used (Sunrise Inc.). These chickens were obtained as embryonated eggs and
hatched under SPF conditions at the John Kirkpatrick Skeeles Poultry Health
Laboratory, University of Arkansas. Due to a poor hatch, the number of inoc-
ulated chickens was less than that used for in vivo study 1 (25 birds/group versus
35 birds/group).
Cell line establishment. Lymphoblastoid cell lines were established from gross
lymphomas essentially as described previously (18, 45), with the exception that a
modified medium was used in the initial culturing of tumor cells (modified
Iscove’s medium, containing 10% fetal bovine serum, 10% chicken serum, 13
insulin/transferrin/selenium, 13 nonessential amino acids, 4 mM L-glutamine,
2 mM sodium pyruvate, 5 mM b-mercaptoethanol, 13 penicillin/streptomycin/
neomycin, and 53 amphotericin B). All cell culture media and reagents were
purchased from GIBCO-BRL.
Flow cytometry analysis of MDCC-UA20 cells. For examination of the level of
spontaneous smGFP expression in cell line MDCC-UA20, a FACSort flow cy-
tometer was used (Becton-Dickinson, San Jose, Calif.). Ten thousand ungated
cells were acquired per sample and subjected to analysis using CellQuest soft-
ware (Becton-Dickinson). For comparison, reticuloendotheliosis virus-trans-
formed cell line RECC-CU91 (53) and MDV-transformed cell lines MDCC-
UA01 and UA04 (18) were also examined for GFP expression.
Nucleotide sequence accession number. The cDNA sequence of vIL-8 de-
scribed in this study has been deposited in GenBank under accession number
AF065430.
FIG. 1. Expression of vIL-8 is dramatically induced in MSB-1 cells
treated with n-butyrate. For analysis, 4 3 106 MSB-1 cells were not
treated (U) or treated with 3 mM n-butyrate (NB) for 48 h at 37°C to
induce virus replication. Total RNA was purified from each sample
and subjected to Northern blot hybridization analysis. Duplicate blots
were prepared for different hybridizations. A distinct 0.7-kb transcript
was identified when a DNA fragment containing vIL-8 sequences was
used as a probe (vIL8). Without NB treatment, at least five transcripts
could be identified using a probe encompassing the latent MDV EcoRI
Q protein Meq (MEQ). As a comparison, chicken cellular rRNAs (28S
and 18S) were stained with ethidium bromide to demonstrate the
cellular transcription level in MSB-1 before and after NB treatment.
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RESULTS
Identification of vIL-8 transcript. In the course of analyzing
spliced variants of MDV oncoprotein Meq (27), we identified
an alternatively spliced Meq-encoding cDNA which fused the
bZIP domain of meq with sequences mapped in the BamHI-L
fragment (L. F. Lee et al., unpublished). This variant is iden-
tical to a 677-bp cDNA first described by Peng et al. (51). For
simplicity, this fusion transcript is referred to as MEQDC-
BamL in this paper. We noticed that the sequences derived
from the BamHI-L region had a structure strikingly similar to
those of CXC chemokines exemplified by IL-8 (see below).
Yet, MEQDC-BamL is unlikely to function as a chemokine
because it lacks a signal peptide but instead is fused to a strong
nuclear and nucleolar localization signal of meq (33). We hy-
pothesized that MEQDC-BamL was derived from an aberrant
splicing product, in which the natural 59 exon(s) of the IL-8-
like chemokine was replaced by the single meq exon. Our
supporting evidence for this was that Northern blot analysis of
MSB-1 RNA, probed with the IL-8 portion of the MEQDC-
BamL sequence, revealed a single 0.7-kb transcript (Fig. 1). By
contrast, the meq probe detected a series of higher-molecular-
weight bands corresponding to differentially processed meq
transcripts as previously described (27), none of which, how-
ever, comigrated with the 0.7-kb transcript.
We examined several MDV-transformed lymphoblastoid
cell lines as possible RNA sources for identifying IL-8 ho-
molog-encoding transcripts. MSB-1, an MDV-transformed
lymphoblastoid cell line (3) that does not express readily de-
tectable levels of MEQDC-BamL, was chosen for this purpose.
We found that treatment of this cell line with n-butyrate, a
FIG. 2. Characterization of transcript encoding vIL-8 by RACE analysis. (A) Schematic drawing of the MDV genome and the location of vIL-8.
Transcripts encompassing meq, meqDC-BamL, and vIL-8 are depicted at the bottom of the diagram with exons in boxes and introns in solid lines.
Abbreviations: IRL, long internal repeat; IRS, short internal repeat; TRL, long terminal repeat; TRS, short terminal repeat; UL, unique long
sequence; US, unique short sequence. (B) Locations of the oligonucleotide primers used in RACE reactions. vIL-8F4 was used as a gene-specific
primer in 39 RACE. vIL-8B1 was used as a gene-specific primer in 59 RACE. vIL-8FL-S and vIL-8FL-AS are primers derived from RACE results
used to amplify the full length of the vIL-8 open reading frame. The empty arrows depict exons II and III present in the meqDC-BamL and vIL-8
sequences. (C) Ethidium bromide-stained agarose gel (1%) demonstrates 0.3- and 0.45-kb PCR amplicons in 59- and 39 RACE reactions,
respectively. Sizes are given on left in kilobases.
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chemical often used to induce the lytic replication of herpes-
viruses (13), appeared to differentially regulate the 0.7-kb and
meq transcripts. Butyrate treatment increased the expression
of the 0.7-kb transcript but appears to have downregulated the
transcription of the meq transcripts (Fig. 1), although this ef-
fect may have been exacerbated by the overall decrease in
RNA yield from the butyrate-treated cells (Fig. 1, ethidium
bromide-stained lanes). These data do suggest, however, that
the 0.7-kb transcript encodes an autonomous IL-8-like chemo-
kine, distinct from the MEQDC-BamL product. mRNA from
n-butyrate-treated MSB-1 cells was therefore used as the
source for RACE analysis of the putative vIL-8 transcript.
Molecular cloning of vIL-8. The RT-PCR-based RACE ap-
proach was used to identify the ends of the vIL-8 cDNA, using
primers derived from the known sequences of the IL-8 portion
of MEQDC-Bam-L (Fig. 2A and B). As shown in Fig. 2C,
antisense primer vIL-8B1 produces a major 59 RACE product
of 0.3 kb. The nucleotide sequence of this product helped
define the 59 end of the cDNA and uncovered a putative
translational initiation site of the open reading frame (see
below). The sense primer vIL-8F4 produced a 39 RACE prod-
uct of 0.45 kb, in which a polyadenylation recognition signal
near the 39end was identified (see below).
To ensure that these two RACE products were derived from
the same transcript, primers vIL-8FL-S and vIL-8FL-AS,
which are located at the ends of the 59 and 39 RACE products,
respectively, were used to amplify the region that expresses the
entire open reading frame of vIL-8 (Fig. 2B). An RT-PCR
FIG. 3. Fine structure of vIL-8 cDNA. (A) The nucleotide sequence of a full-length cDNA compared to its genomic counterpart. cDNA
sequences are in capitals and blocked by lines while consensus splice donor/splice acceptor in introns are in bold. Putative TATA box (TATATAA)
and polyadenylation recognition (ATTAAA) sequences are underlined. Deduced amino acid sequences are shown beneath the nucleotide se-
quences. The 17 hydrophobic residues of the first exon are in boldface. Four cysteines conserved in all CXC chemokines are circled. (B) Alignment
of amino acid sequences of vIL-8 and various mammalian and avian IL-8 homologs. The four conserved cysteines and the signature ELR motif
are indicated on top of the alignment. Similar (shaded in light gray) and identical (shaded in dark gray) amino acids are indicated. The abbreviation
used and GenBank accession number for each sequence are rhIL8 (rhesus macaque IL-8), P51495; huIL8 (hIL-8), P10145; ovIL8 (ovine IL-8),
P36925; doIL8 (dog IL-8), JN0841; rabIL8 (rabbit IL-8), P19874; 9E3/CEF4 (CEF protein 9E3), M16199; moGro (mouse Gro), P12850; moMIP2 (mu-
rine macrophage inflammatory protein 2), P10889; moBLC (Mus musculus B-lymphocyte chemoattractant), AF044196; and ratPF4 (rat PF4), P06765.
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product of 454 bp was obtained, and the complete sequence of
this amplicon (capital letters) superimposed on the BamHI-L
genomic sequences is depicted in Fig. 3A. This alignment re-
veals three exons in the cDNA: the first exon is 80 bp long, with
an initiation methionine located at nt 17 to 19 (the beginning
of the cDNA is hereby set as nt 1). Exons II and III are iden-
tical to those found in meq–BamHI-L (51), which we recog-
nized as the IL-8-like domains. The entire cDNA thus encodes
a 134-amino-acid polypeptide with the hallmarks of a CXC
chemokine: (i) exon I contains 21 amino acids; (ii) exons II and
III contain 4 cysteines (circled) which are positionally con-
served in all CXC chemokines; (iii) the overall amino acid
sequences share significant homology with the IL-8 family of
chemokines (see below). In addition, a consensus TATA box,
TATATAA, is found at 232 nt and, as described above, a non-
canonical polyadenylation sequence, ATTAAA, is located 15
nt upstream of the 39 end and adjacent to the translational stop
of vIL-8 exon III. These results suggest that vIL-8 has its own
transcriptional unit in the MDV genome and that the previ-
ously described MEQDC-BamL transcript may represent an
aberrant or alternatively spliced product.
Comparison of vIL-8 with cellular IL-8 genes. The vIL-8
amino acid sequence was compared to sequences in the pres-
ent database using BlastSearch. Sequences with the highest
homology scores were those from IL-8 and its related CXC
chemokines, such as Gro and platelet factor 4 (PF4) (Fig. 3B),
all of which are implicated in the chemotaxis and inflammatory
responses (5). Noticeably, chicken 9E3/CEF4 (9, 64) and K60
(61), postulated to be the avian orthologs of IL-8 (7), were also
identified in this analysis. The overall amino acid sequence
identities between vIL-8 and human IL-8, vIL-8 and 9E3/
CEF4, and vIL-8 and mouse Gro are 23, 22, and 20%, re-
spectively. Despite the significant similarities with viral and
mammalian IL-8s, there is an interesting difference: the
3-amino-acid motif ELR (glutamate-leucine-arginine), which
immediately precedes the first CXC motif and is thought to be
the determinant of the neutrophil specificity, is conspicuously
absent. In place of this ELR motif is a DKR (asparate-lysine-
FIG. 4. Expression kinetics of vIL-8 in MSB-1 cells. (A) MSB-1 cells were treated with n-butyrate (3 mM) for 0 to 48 h, as indicated. For the
36-h time point, duplicate cell cultures were prepared for the treatment of cells with PAA (100 mM). Total RNAs were extracted at the end of
chemical treatment, and concentrations were determined. Twenty micrograms of RNA from each sample was loaded to each lane, and duplicate
filters were prepared for vIL-8 hybridization (upper gel) and GAPDH hybridization (lower gel) (33). (B) RNA was purified from RB1B-infected
CEF that were not treated (left lanes), treated with 100 mg of CHX/ml (center lanes), or treated with 100 mg of PAA/ml (right lanes) and was used
as the template for RT-PCR. For each RNA treatment group, three concentrations of RNA were used (500, 50 and 5 ng, left to right, respectively).
RT-PCR was performed as described in the text, and the entire reaction products (total, 25 ml) were loaded on a 1% agarose gel. The products
for RT-PCR were ICP27, 670 bp; RRL, 549 bp; gC, 584 bp; vIL-8, 699 bp (unspliced) and 423 bp (spliced); and Meq, 421 bp (Table 1). Arrows
indicate the RT-PCR products of the appropriate size. Far right lanes contain molecular size markers (Hyper-Ladder; Bioline). (C) Ethidium
bromide-stained agarose gel of 1 mg of each RNA used for RT-PCR analysis in panel B, demonstrating that the RNAs used were not degraded.
Mrk, Hyper-Ladder DNA size markers in base pairs. Un, untreated.
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arginine) motif. There are other IL-8-like chemokines that do
not have ELR motifs. such as PF4 and the recently discovered
B-lymphocyte chemoattractant (22, 32). In both cases, the pri-
mary target cells are not neutrophils. This raises an intriguing
question about the target cell specificity of vIL-8.
Expression kinetics of vIL-8. To understand the role of
vIL-8 in the MDV life cycle, we first determined the kinetics of
vIL-8 expression. Initially, log-phase MSB-1 cells were treated
with n-butyrate for different time periods, in combination with
herpesvirus DNA polymerase inhibitor PAA (21). Total RNAs
from each sample were subjected to Northern blot analysis
using the vIL-8 cDNA fragment as a probe. As mentioned
before, there was a basal level of vIL-8 expressed in untreated
MSB-1 cells, presumably due to a small population of cells
undergoing reactivation (Fig. 4A, lane 1). The induction fol-
lows relatively slow kinetics and was evident only after 36 h of
treatment. Furthermore, this induction was largely inhibited by
PAA treatment (Fig. 4A, lane 6), suggesting that vIL-8 is a lytic
transcript with true late (g2) kinetics (21).
To firmly establish the kinetics of vIL-8 expression during
MDV infection, CEF were infected with MDV (RB1B) in the
presence and absence of CHX and PAA (Fig. 4B). As controls
for IE, early (E), and true late (L, g2) genes, primers were
designed to amplify MDV ICP27, RRL, and gC gene products.
In addition, primers specific for the meq gene were used to
establish the kinetics of Meq expression during lytic infection.
Our results (Fig. 4B) clearly demonstrate that vIL-8 is ex-
pressed with true late kinetics, as its expression is blocked by
both CHX and PAA. A problem with kinetic analysis of MDV
gene expression is the carryover of transcripts of all kinetic
classes present in the inoculum. This carryover does allow for
some background expression of RRL, gC, and vIL-8 genes in
the presence of CHX and/or PAA (Fig. 4B). This level of
expression is minor, however, and RRL expression is largely
blocked by CHX but not by PAA, and gC and vIL-8 expression
is largely inhibited by CHX and PAA. Aiding in this assess-
ment of expression is the use of 3 orders of magnitude (500, 50,
and 5 ng) of template, which allows clear distinction among the
three kinetic classes.
Interestingly, we determined that meq is apparently ex-
pressed as an IE gene during lytic infection. These data, as well
as our Northern blot results for meq expression, must be viewed
from the standpoint that both techniques do not provide in-
formation regarding the sense or antisense nature of the tran-
scripts detected. This is a particularly important consideration
for this region of the genome, as both sense and antisense tran-
scripts have been detected during latent and lytic infection (50).
In any event, our data do indicate that vIL-8 is expressed as
a true late gene and therefore is likely to be involved in the
replication (lytic) phase of MDV. Given its similarity to cellu-
lar chemokines, one possible role of vIL-8 is the recruitment of
target cells for MDV infection. As a first step to test this
hypothesis and to demonstrate that vIL-8 is biologically active,
we chose the baculovirus expression system to obtain recom-
binant vIL-8 for chemotaxis studies.
Expression and purification of recombinant MDV vIL-8. To
facilitate the purification of baculovirus-expressed protein, the
vIL-8 open reading frame was tagged with six contiguous his-
tidines at its C terminus. Cell culture supernatant from insect
cells infected with vIL-8–His recombinant baculoviruses was
partially purified by passing through an Ni-nitrilotriacetic acid
affinity column followed by gel filtration chromatography (Fig.
5). A protein band with an apparent molecular mass of 18 to 20
kDa in SDS-PAGE was eluted from the affinity column (Fig.
5A, fractions 3 and 4). After gel filtration, the pooled fraction
(42- to 44-min fractions) contained primarily the vIL-8–His
protein (Fig. 5B), which was used for subsequent studies. Fur-
ther verification that the 18-kDa band was indeed vIL-8 came
from the observations that a monoclonal antibody against the
C-terminal six histidines and rabbit antisera against two syn-
thetic peptides derived from the deduced vIL-8 open reading
frame also showed immunoreactivity to this protein (data not
shown). The elution behavior of this protein in gel filtration
(corresponding to an apparent molecular mass of 12 to 15
kDa) suggests that the majority of the recombinant vIL-8–His
exists in a monomer form. In addition, the fact that the recom-
binant vIL-8–His was isolated from the supernatant suggests
that the signal sequence is functional, resulting in the secretion
of the vIL-8 protein.
MDV vIL-8 as a chemoattractant for chicken PBMC. A
major function of chemokines is chemotaxis. Thus, we first
tested whether vIL-8 is able to recruit chicken PBL. Freshly
prepared chicken blood samples were fractionated through a
Percoll gradient, which gave rise to two distinct bands, namely,
PBMC and heterophils. The PBMC fraction contained mono-
cytes, thrombocytes, and lymphocytes, whereas the heterophil
fraction was principally the chicken equivalent of human neu-
trophils. Chemotaxis assays were conducted using a modifica-
tion of the method described by Boyden (10). The purified
vIL-8 protein fractions were assayed for chemotactic activity by
placing the protein to be tested in the medium, which was
FIG. 5. Purification of six-His-tagged vIL-8 produced by baculovi-
rus expression system. (A) Purification of recombinant vIL-8–His by
Ni-affinity column chromatography. Cell-free supernatants collected
from High Five insect cells infected with vIL-8–His recombinant bac-
ulovirus were prepared and loaded onto a Ni column as described in
Materials and Methods. Bound vIL-8–His was eluted by a 20 to 500
mM imidazole gradient. Twenty microliters of each elution fraction
was loaded onto an SDS–10 to 20% PAGE gel, separated electro-
phoretically, and stained with Coomassie blue. Kd, kilodaltons. (B)
Silver staining demonstrates the purity of vIL-8–His after gel filtration.
Elution fractions 3 and 4 of the Ni column were pooled, concentrated
eightfold by Centricon-3 spin concentration, and further purified by gel
filtration chromatography (Superose 12). Fractions were collected ev-
ery 2 min at a flow rate of 0.4 min/ml. Purity of the eluent with the
highest chemotaxis activity (42- to 44-min fractions) was analyzed by
SDS–10 to 20% PAGE followed by silver staining. A major protein
band with a size of approximately 20 kDa is indicated with an asterisk.
5166 PARCELLS ET AL. J. VIROL.
separated from the target cells by a membrane (3- to 5-mm
thickness). The number of cells migrating through the mem-
brane in response to the protein was counted, and the results
are shown in Fig. 6. MDV vIL-8 exhibited a strong chemotactic
activity toward chick PBMC, with the maximal response elic-
ited at a concentration of 42 nM (Fig. 6A, upper panel). At a
higher concentration (84 nM), the activity decreased, consis-
tent with previous reports that receptors are downmodulated
after full occupancy (8, 35). Recombinant hIL-8 also elicited
a positive response (Fig. 6A, lower panel), although a higher
concentration of ligand was required. In contrast, when
chicken heterophils were used as targets, hIL-8 exhibited a
strong effect at 21 nM, while vIL-8 failed to “chemoattract” the
heterophils at all concentrations tested (Fig. 6B). These data
suggest that MDV vIL-8 is biologically active and functions like
a chemokine. They also reveal an interesting difference in
target cell specificity between vIL-8 and hIL-8. We have re-
cently received clones of the chicken IL-8 orthologs 9E3/CEF4
and K60 (62; a gift from Peter Staeheli, University of Freiburg)
and plan to investigate the possible interactions of vIL-8 with
native chicken IL-8 signaling and chemotaxis.
The MDV vIL-8 gene is nonessential for replication in cell
culture. Given the location of vIL-8 in the MDV genome, i.e.,
within the repeats flanking the UL region downstream of the
meq gene, and the difference in expression patterns between
meq and the vIL-8 gene, we felt that vIL-8 is likely to be
important in MDV infection. Most genes expressed within
herpesvirus repeats are involved in the regulation of gene
expression (39), and this region is of particular interest in the
MDV genome, as this region is unique to serotype 1 (onco-
genic) MDVs (25, 44).
To examine the role of vIL-8 during MDV infection, there-
fore, we constructed a deletion mutant having both copies of
the vIL-8 coding sequences (long terminal repeat [TRL] and
long internal repeat [IRL]) removed and replaced with a smGFP
expression cassette (Fig. 7A). The smGFP expression cassette
was inserted between NcoI and ClaI sites in the BamHI-L
fragment, resulting in the deletion of all three exons encoding
vIL-8. Mutant viruses constructed using this mutated BamHI-L
fragment were examined structurally for deletion of both of the
vIL-8 coding regions. Of four clones constructed, three were
found to have deleted both copies of the vIL-8 region (data not
shown). Clone 2, designated RB1BvIL-8DsmGFP, was exam-
ined further via PCR, Southern blot hybridization, and RT-
PCR analysis (Fig. 7B and 8). Using primers that flank the site
of deletion, PCR products of 939 and 1,948 bp were observed
when parent virus (RB1B)- and deletion mutant (RB1BvIL-
8DsmGFP)-infected CEF DNA were used as templates, respec-
tively. Moreover, Southern blot hybridization analysis of these
PCR products demonstrated that the vIL-8 coding regions
FIG. 6. Chemotaxis assays demonstrate that MDV vIL-8 is a functional chicken PBMC chemoattractant. The chemotactic activity of vIL-8
toward chicken PBMC (A) or heterophils (B) was assayed using Costar Transwell plates. For panel A, chemotaxis was performed using
5-mm-pore-size Transwell plates with the indicated concentrations of vIL-8 at 37°C for 40 min. For panel B, a 3-mm-pore-size Transwell plate was
used for heterophils and the incubation was increased to 1 h. In each assay, a positive control consisting of medium with 15 mg of fibronectin and
a negative control containing medium alone were included. Results were averaged from at least three independent experiments. u, control; o,
vIL-8; M, hIL-8. HTP, high-power field.
VOL. 75, 2001 MDV-ENCODED CHEMOKINE vIL-8 5167
were, in fact, absent from the genome of RB1BvIL-8DsmGFP,
RB1BvIL-8DsmGFP reisolated from chickens (spleen cells) dur-
ing in vivo infection, and from a cell line established from an
RB1BvIL-8DsmGFP-induced tumor (MDCC-UA20) (Fig. 7B).
To demonstrate a functional absence of vIL-8 expression
associated with deletion of these regions from the MDV ge-
nome, we performed RT-PCR analysis using primers specific
for cellular actin (cellular and DNA contamination control),
smGFP (RB1BvIL-8DsmGFP control), ICP27 (for MDV in-
fection control), and vIL-8 expression (Fig. 8). To compare
relative levels of expression among these genes, we selected
primers that generated small products (200 to 700 bp) and used
RNA template concentrations spanning 3 orders of magnitude
(1 mg, 100 ng, and 10 ng). Results using chicken b-actin prim-
ers indicate that comparable levels of RNA are present in all
samples and that this RNA is devoid of DNA contamination
(Fig. 8A). The primers specific for smGFP amplification dem-
onstrate that this gene is expressed in abundance in infected
cells and is readily detectable in 10 ng of total RNA (Fig. 8B).
The level of smGFP expression, however, appeared lower than
that of ICP27, an IE gene (Fig. 8C). The level of ICP27 expres-
sion, in fact, was comparable among RB1B- and RB1BvIL-
8DsmGFP-infected CEF RNAs, demonstrating that cells were
infected to comparable levels. The high abundance of ICP27
message may be explained by the fact that the MDV ICP27
gene is downstream of glycoprotein K (gK), with no transcrip-
tional terminator between the translational stop of gK and the
initiation codon of ICP27 (56). Consequently, our ICP27 prim-
ers detect ICP27-specific transcripts as well as gK read-through
transcripts. For our intents and purposes, however, these RT-
PCR products demonstrate comparable levels of MDV infec-
tion between the parental (Fig. 8, lanes 4 to 6) and recombi-
nant (Fig. 8, lanes 7 to 9) infected CEF.
Using primers spanning exons I and III of vIL-8, we found
readily detectable levels of vIL-8 expression in RB1B- but not
RB1BvIL-8DsmGFP-infected CEF RNA, correlating a func-
tional loss of expression with deletion of both copies of the
gene from the genome (Fig. 8D). The level of vIL-8 expression
appeared less than the expression of ICP27, and unspliced and
single-spliced forms of the vIL-8 transcripts were clearly visi-
ble. These products are unprocessed and partially processed
RNAs, as RT-PCR analysis using the primers employed in
structural analysis (Fig. 7A), which contained one primer
downstream of the putative poly(A) site, failed to amplify any
products from RB1B- or RB1BvIL-8DsmGFP-infected CEF
RNAs (data not shown).
In vivo replication of RB1BvIL-8DsmGFP. To examine the
effect of vIL-8 deletion on the ability of MDV to replicate and
induce pathology in chickens, we performed two in vivo exper-
iments (Fig. 9 and 10). In in vivo experiment 1, RB1BvIL-
8DsmGFP replicated to lower levels than an equal-passage
level parent virus (RB1Bp21) or a recombinant RB1B having
a GFP expression cassette inserted at the nonessential US2 gene
(RB1BUS2gfpD-2) (18) (Fig. 9). This impairment in replica-
tion was particularly evident in reisolation attempts from PBL,
from which RB1BvIL-8DsmGFP could be reisolated only at
weeks 2 and 3 postinoculation. Given that the US2gfp recom-
binant was inoculated at one-third the dosage of RB1BvIL-
8DsmGFP (313 PFU/bird vs. 948 PFU/bird, respectively), it
does not appear that the decrease in virus replication for
FIG. 7. Structural characterization of RB1BvIL-8DsmGFP. (A)
Schematic diagram of the MDV genome showing the region expressing
the vIL-8 gene, the restriction sites used in the deletion of vIL-8, the
smGFP expression cassette used in mutagenesis, and the location of
PCR primers used in the structural characterization of the parental
and mutant viruses. (B) An agarose gel showing the results of PCR
amplification using primers 1 and 4 (shown in panel A) (upper left
panel) and Southern blot hybridization analysis of these products us-
ing the BamHI-L fragment of the MDV genome (upper right panel),
the vIL-8 cDNA (lower left panel), and the smGFP gene (lower right
panel) as probes. The lanes are ld3, HindIII-digested lambda DNA
molecular weight markers; 123, 123-bp DNA ladder markers (GIBCO-
BRL); BamL, pUC19 containing the BamHI-L fragment of the MDV
genome (20); pYH, transfer vector pYH6a; CEF, uninfected CEF
DNA; RB, RB1B parental MDV-infected CEF DNA; V1, RB1BvIL-
8DsmGFP clone 2-infected CEF DNA; V2, RB1BvIL-8DsmGFP rei-
solated from spleen cells of infected chickens; and UA20, DNA from
cell line MDCC-UA20, established from an RB1BvIL-8DsmGFP-in-
duced ovarian lymphoma.
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RB1BvIL-8DsmGFP in vivo can be attributed to GFP expres-
sion. Despite this significant growth impairment, RB1BvIL-
8DsmGFP was able to induce tumors in two birds (Fig. 9B) and
a cell line was established from one of these tumors (MDCC-
UA20). The ability to establish a T-cell line using RB1BvIL-
8DsmGFP indicates that (i) the vIL-8 gene is nonessential for
transformation and that (ii) even high levels of smGFP expres-
sion are tolerated by many chicken cell types.
In vivo experiment 1 employed B15 3 7 chickens, which are
genetically defined and highly susceptible to MDV pathology,
particularly to neurological lesions (68). To assess the ability of
RB1BvIL-8DsmGFP to replicate in genetically outbred, com-
mercial SPF chickens, we performed an additional in vivo
experiment (Fig. 10). During in vivo study 2, the reisolation
levels of RB1BvIL-8DsmGFP from spleen cells and PBL were
again an order of magnitude less than the levels of parent virus
(RB1Bp12). In this study, RB1BvIL-8DsmGFP induced one
tumor, indicating that this virus retained oncogenicity unre-
lated to the genetic susceptibility of the chickens infected.
Taken together, these results demonstrate that the vIL-8
gene is nonessential for MDV replication in cell culture, dur-
ing in vivo infection, and moreover, for transformation of
chicken T cells. As hypothesized, given the timing of expres-
sion of vIL-8, the function of vIL-8 is likely to be associated
with lytic infection, perhaps affecting target cell access or re-
cruitment. Our current lack of a rescue mutant, however, limits
our conclusions with regard to specific deficits in replication
due to the possibility of MDV spontaneous mutation when
passaged repeatedly in cell culture.
The smGFP cassette inserted at the vIL-8 loci is constitu-
tively expressed in the cell line MDCC-UA20. Having excised
an RB1BvIL-8DsmGFP-induced ovarian lymphoma during in
vivo experiment 1, we noted that, like other GFP- and Lac-
expressing MDVs, the marker gene was apparently repressed
in situ and in the initial stages of cell culture (18; data not
shown). Upon culturing these cells and after cell line estab-
lishment, we noted, via microscopic examination, spontaneous
smGFP expression in a low but consistent number of cells
(data not shown). We reported this observation previously for
an RB1BUS2gfpD-1-transformed lymphoblastoid cell line (18)
and several lac-containing MDV-transformed cell lines (46).
By flow cytometry, however, we determined that the UA20 cell
line constitutively expressed detectable levels of smGFP
(Fig. 11) compared to non-MDV-transformed (CU91), paren-
tal RB1B-transformed (UA01), and RB1BUS2gfpD-1-trans-
formed (UA04) cell lines. These data suggest that there is
constitutive expression of the smGFP cassette in the context of
the latent MDV genome. This expression could be due to (i)
copy number of the expression cassette, (ii) the location of the
cassette within the repeats versus unique sequences of the
MDV genome, or (iii) the location of the cassette downstream
of the meq gene, a well-characterized latent gene (27), result-
ing in read-through transcripts from meq in the transformed
cells.
FIG. 8. Expression analysis of uninfected and RB1B- and RB1BvIL-8DsmGFP-infected CEF RNAs. The expression of cellular and virus gene
products was examined using RT-PCR and primers specific for chicken b-actin (exon IV3exon V) (A); the smGFP gene (B); the MDV ICP27
gene (C); and the MDV vIL-8 gene (exon I3exon III) (D). Each picture shows the ethidium bromide-stained 1% agarose gel of 10 ml of each reaction
product (total reaction volume, 50 ml). The templates used were lanes 1 to 3, 1 mg, 100 ng, and 10 ng of CEF total RNA, respectively; lanes 4 to
6, 1 mg, 100 ng, and 10 ng of RB1B-infected CEF total RNA, respectively; lanes 7 to 9, 1 mg, 100 ng, and 10 ng of RB1BvIL-8DsmGFP-infected
CEF total RNA, respectively. Lane 10 in panel D represents 20 ng of RB1B-infected CEF DNA as a control for DNA contamination. HL denotes
DNA Hyper-Ladder molecular size standard (Bioline). Sizes of specific RT-PCR products and molecular size standards are identified with arrows.
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DISCUSSION
We describe here the identification and cloning of a novel
chemokine encoded by MDV, termed vIL-8. vIL-8 mRNA is
transcribed from the IRL region of the MDV genome via two
splicings. Deduced amino acid sequence of vIL-8 cDNA re-
veals a significant similarity with mammalian IL-8 families,
including a prototypical signal peptide and four positionally
conserved cysteines. Baculovirus-expressed vIL-8 was shown to
be functional as a secreted protein and as a chemoattractant
for chicken mononuclear cells.
The alignment of cDNA and genomic sequences identifies
three exons for the 0.7-kb vIL-8 mRNA. The N-terminal 21
amino acids encoded by exon I are rich in hydrophobic resi-
dues (80%) and likely to serve as a signal peptide (16). Exons
II and III constitute the secreted portion of vIL-8. The highly
conserved motifs and spacing classify vIL-8 as a member of the
IL-8-like CXC family. Consequently, vIL-8 is the first reported
CXC chemokine encoded by an alphaherpesvirus (34). Re-
cently, CMV has also been shown to encode Gro-a/IL-8-like
chemokines (UL146, UL147) (49). Aside from these examples,
most other viruses encode homologs of either CC chemokines
or CXC chemokine receptors. While the overall structure of
vIL-8 is similar to those of CXC chemokines, vIL-8 carries an
unusually long C-terminal extension. Whether and how this
long C terminus modulates the binding to receptors or to poly-
glycans remains to be determined.
The crucial residues involved in binding of CXC chemokines
to receptors have been mapped to the N terminus. In partic-
ular, the three residues right before the CXC motif are deemed
to be essential (15, 23). Mutations or deletions of them render
the molecules incapable of recruiting target cells. All IL-8-like
molecules that target neutrophils carry the tri-amino acids
ELR in these positions (5). Chemokine PF4, which carries
DLS (or DLQ) in these positions, fails to attract neutrophils.
Addition of ELR residues to an N-terminally truncated PF4
increases its chemotactic potential for neutrophils (14). In
vIL-8, DKR, a putative hybrid motif of ELR and DLS, is
present in this region. Interestingly, the UL147 gene product of
CMV (vCXC-2) contains a DRR motif at these positions,
suggesting a possible similarity of function between this beta-
herpesvirus-borne CXC chemokine and MDV-borne vIL-8
(49). Thus, it is difficult to predict whether vIL-8 has a tropism
toward neutrophils. Our chemotaxis experiments suggest that
vIL-8, unlike hIL-8, is more potent as a chemoattractant for
chicken mononuclear cells than for heterophils. We hoped that
this comparison could be extended to chicken IL-8 homologs
FIG. 9. Comparison of RB1B and RB1BvIL-8DsmGFP, in vivo ex-
periment 1. (A) Graphs of virus reisolation data for spleen cells and
PBL from chickens (B15 3 7) inoculated with mock-infected CEF
(Mock); equal-passage-level parent virus-infected CEF (RB1Bp21);
RB1BUS2gfpD-2-infected CEF (US2gfpD-2); and RB1BvIL-8DsmGFP-
infected CEF (vIL-8D). The numbers in parentheses indicate PFU
inoculated per chicken. Each time point represents the mean plaque
number counted on triplicate 60-mm-diameter dishes of CEF coculti-
vated with spleen cells or PBL at 6 days postplating. The y axis denotes
plaques formed on CEF monolayers per 106 cell plated. (B) Summary
of virus-specific mortality and tumor incidence data for this trial. Num-
bers in parentheses indicate the actual number of birds containing
tumors divided by the number of birds left in treatment groups after
virus reisolation attempts (i.e., after 4 weeks postinoculation).
FIG. 10. Comparison of RB1B and RB1BvIL-8DsmGFP, in vivo
experiment 2. (A) Graphic representations of virus reisolation data for
spleen cells and PBL from commercial SPF chickens inoculated with
mock-infected CEF (Mock); parent virus (RB1B)-infected CEF
(RB1Bp12); and RB1BvIL-8DsmGFP-infected CEF (vIL-8D). Each
time point represents the mean plaque number counted on triplicate
60-mm-diameter dishes of CEF cocultivated with spleen cells or PBL
at 6 days postplating. The numbers in parentheses indicate PFU inoc-
ulated per chicken. The y axis denote plaques formed on CEF mono-
layers per 106 cell plated. (B) Summary of virus-specific mortality and
tumor incidence data for this trial. Numbers in parentheses indicate
the actual number of birds containing tumors divided by the number of
birds left in treatment groups after virus reisolation attempts (i.e., after
4 weeks postinoculation).
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(62). Unfortunately, we were unable to obtain purified chicken
IL-8 homologs for this study and plan to construct expression
vectors for both 9E3/CEF4 and the recently discovered K60
genes to investigate the possible interactions of vIL-8 with
native chicken IL-8 signaling and chemotaxis. In addition, fu-
ture experiments are required to determine more precisely
which cell types in the chicken mononuclear cell fraction are
the authentic targets for vIL-8.
While this is the first IL-8-like molecule found to be encoded
by an alphaherpesvirus, the association of cellular IL-8 expres-
sion with viral infection has long been documented. Cultures of
corneal keratinocytes infected with herpes simplex virus type 1
were shown to synthesize at the rate of more than 30 ng per
million cells of IL-8 during an 18-h incubation (43). Similarly,
the induction of IL-8 synthesis could be demonstrated in hepa-
tocytes infected with hepatitis B virus, monocytes infected with
human CMV, fibroblasts infected with human herpesvirus 6, or
leukemia cells infected with human T-cell leukemia virus I (22,
36, 42). IL-8 is known as an important mediator of inflamma-
tion which recruits and activates neutrophils to sites of infec-
tion, often inducing some of the symptoms associated with
virus infections (1, 5). An IL-8-activated neutrophil is charac-
terized by enhanced migration, phagocytosis, superoxide gen-
eration, and granule release (6). It has also been recognized
that signals transduced by the interaction of IL-8 with IL-8R, a
G-protein-coupled receptor, are responsible for the activation
of neutrophils. Recently, the observation that members of the
p21-activated kinase family of kinases are transiently activated
in neutrophils stimulated with IL-8 further elucidated the mo-
lecular process of IL-8 signaling (24). Taken together, the
overproduction of cellular IL-8 in viral infections could be a
reactive response of the host cells, aimed at reducing viral load.
If the function of cellular IL-8 is to curtail the production of
viruses at entry into a host, then why does MDV encode an
IL-8-like gene? Obviously, a great deal has yet to be learned
before this question can be answered, and we can only specu-
late on some of the plausible reasons. First, vIL-8 may be
involved in recruiting and/or activating phagocytic cells in the
lungs (macrophage, dendritic cells, and heterophils), the pri-
mary site of MDV entry (12). This recruitment or activation
may aid in the early transmission of MDV to the primary
lymphoid organs. A similar dissemination function has been
postulated for vCXC-1 (the UL146 gene product) encoded by
CMV (49).
Second, as suggested by this study, the target of MDV vIL-8
may not be neutrophils but rather B or T cells. It is known that
MDV infection in vivo is comprised of an early cytolytic infec-
tion of B cells, followed by a latent infection of T cells. The
recruitment of B and T cells is therefore crucial to the initial
establishment of infection. Expression of vIL-8 may help re-
cruit proper target cells for MDV. Third, vIL-8 may serve as a
decoy for chicken IL-8. We have found that baculovirus-ex-
pressed vIL-8 does not elicit calcium mobilization in either
heterophils or mononuclear cells (data not shown). Cellular
IL-8 is known to form dimers when present at high concentra-
tions (6). Therefore, it is possible that vIL-8 may antagonize
host IL-8 by either competing for binding to the receptor or the
formation of an inactive dimer. The absence of calcium mobi-
lization as a result of vIL-8-binding may be due, however, to
the absence of additional protein modifications not catalyzed
in insect cells, and the above observation must therefore be
viewed with this caveat.
A recently discovered CC-like chemokine scavenger, called
the M3 protein, encoded by murine gammaherpesvirus 68,
shows remarkably broad cellular receptor usage, binding to
certain CC, CXC, and CX3C receptors (49, 65) and inhibiting
the signaling of these receptors. Therefore, vIL-8 may prefer-
entially attract target cells while blocking the attraction of
other leukocytes.
An additional possibility is that vIL-8 may augment MDV
gene expression and enhance viral replication. It has been
demonstrated that the exposure of human fibroblasts to IL-8
augments both infectious virus production and replication of
CMVs at least eightfold (41). This is understandable, since the
signals responding to IL-8 stimulation, such as p21-activated
kinase phosphorylation and calcium mobilization, are also
those which activate transcription factors. If B or T cells carry
receptors that interact with vIL-8, the IL-8 signals may act
upon viral or cellular promoters that transcribe genes condu-
cive for viral replications. In this regard, it is noteworthy that
the newly discovered B-lymphocyte chemoattractant chemo-
kine, which shares significant homology with vIL-8, binds a
receptor specific for B cells, known as BLR (22, 29).
The phenotype exhibited by the deletion mutant virus,
RB1BvIL-8DsmGFP, in vivo does provide some insight into
the possible function of vIL-8. This mutant showed marked
growth impairment in spleen cells and PBL, despite wild-type
replication in cell culture (data not shown). If vIL-8 were
required for enhanced viral gene expression during the lytic
infection of fibroblasts, cells that normally express IL-8 recep-
tor (59), then ablation of this gene would be likely to affect
ability of this virus to replicate in fibroblasts. Our results sug-
gest that vIL-8 is likelier to be involved in leukocyte target
recruitment or immunoevasion, as RB1BvIL-8DsmGFP estab-
FIG. 11. Spontaneous expression of smGFP in MDCC-UA20 cells.
Histogram plots of flow cytometry data are shown depicting the num-
ber and fluorescence intensity of GFP-expressing lymphoblastoid cells.
The x axis denotes arbitrary fluorescence units (log scale) for the FL-1
(fluorescein isothiocyanate [FITC], GFP) channel, and the y axis de-
notes cell number. For each plot, 104 cells were acquired. The cell lines
used were RECC-CU91, a REV-transformed T-lymphoblastoid cell
line (53); MDCC-UA01, an RB1B-transformed T-lymphoblastoid cell
line (18); MDCC-UA04, an RB1BUS2gfpD-1-transformed T-lympho-
blastoid cell line (18); and MDCC-UA20, an RB1BvIL-8DsmGFP-
transformed T-lymphoblastoid cell line.
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lished a poor lytic infection and was largely cleared from in-
fected chickens by 4 weeks postinoculation. Despite this poor
initial infection, however, RB1BvIL-8DsmGFP retained the
ability to transform T cells, suggesting that its abilities to es-
tablish and maintain latency were not abrogated. Our conclu-
sions regarding the phenotype of RB1BvIL-8DsmGFP must be
viewed with the caveat that a rescue mutant has not yet been
generated. From RB1BvIL-8DsmGFP-infected chickens, we
have isolated viruses that have deleted the smGFP expression
cassette, and one of these has been plaque purified and pas-
saged in vivo (data not shown). This virus, termed NF-1, has
deletions of vIL-8, the smGFP cassette, and additional flanking
sequences. We plan to use this virus for the reinsertion of the
vIL-8 gene at another locus to confirm our observations re-
garding the function of vIL-8 in MDV in vivo infection.
The constitutive expression of smGFP in the RB1BvIL-
8DsmGFP-transformed cell line UA20 is interesting, consider-
ing previous findings with heterologous promoters inserted
within the MDV genome (18, 48). This constitutive expression
likely reflects a difference in structure and/or expression of the
IRL/TRL during MDV latent infection, since a construct con-
taining another GFP (S65T; Clontech, Palo Alto, Calif.) ex-
pressed using the same promoter (CMV) inserted at the US2
locus was repressed in the tumor and is largely repressed in a
derived cell line (18) (Fig. 11).
In summary, we have identified an IL-8-like molecule en-
coded by MDV. This gene is expressed as a true late gene
during lytic infection, suggesting its involvement in viral repli-
cation. We have further shown that baculovirus-expressed
vIL-8 is functionally active as a secreted protein that attracts
chicken PBMC. A recombinant MDV having both copies of
the vIL-8 gene deleted from the genome failed to express vIL-8
transcripts, replicated to wild-type levels in cell culture, yet
showed marked growth impairment in vivo. Despite this
growth impairment, the vIL-8 deletion virus was capable of
inducing tumors, demonstrating that this gene is nonessential
for transformation of chicken T cells. A cell line derived from
a vIL-8 deletion mutant-induced tumor showed constitutive
expression of a marker gene, suggesting that these regions of
the genome (the repeats flanking the UL region) have the
capacity to be transcriptionally active in MDV cell lines. The
present study provides a basic framework to understand how
this viral chemokine (virokine) functions in MDV replication
and in cell-type specific virus-host interactions.
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